It is not known whether oliceridine is present in human milk. The effects of oliceridine on a breastfeeding infant and on milk production have not been evaluated.
- TRADE NAME: Olinvyk (Trevena)
- INDICATIONS: Analgesic for management of acute pain.
- CLASS: Opioid agonist
- HALF-LIFE: 1.3–3 hours (unmetabolized); ~44 hours (metabolites)
- FDA APPROVAL DATE: 08/07/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Buprenorphine, Bupropion, Butorphanol, Carbamazepine, Central nervous system depressants, CYP2D6 inhibitors, CYP3A4 inducers, CYP3A4 inhibitors, Erythromycin, Fluoxetine, Ketoconazole, Nalbuphine, Paroxetine Hydrochloride, Pentazocine, Phenytoin, Quinidine, Rifampin, Ritonavir, Serotonergic agents - PREGNANCY: May cause fetal harm.
- See adverse reactions attributed to class:
ADDICTION, ABUSE AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CENTRAL NERVOUS SYSTEM (CNS) DEPRESSANTS.
OLICERIDINE EXPOSES PATIENTS AND OTHER USERS TO THE RISKS OF OPIOID ADDICTION, ABUSE, AND MISUSE, WHICH CAN LEAD TO OVERDOSE AND DEATH. ASSESS EACH PATIENT’S RISK BEFORE PRESCRIBING, AND MONITOR REGULARLY FOR THE DEVELOPMENT OF BEHAVIORS OR CONDITIONS.
SERIOUS, LIFE-THREATENING, OR FATAL RESPIRATORY DEPRESSION MAY OCCUR. MONITOR FOR RESPIRATORY DEPRESSION, ESPECIALLY DURING INITIATION OR FOLLOWING A DOSE INCREASE.
PROLONGED USE OF OLICERIDINE DURING PREGNANCY CAN RESULT IN NEONATAL OPIOID WITHDRAWAL SYNDROME, WHICH MAY BE LIFE-THREATENING IF NOT RECOGNIZED AND TREATED. IF PROLONGED OPIOID USE IS REQUIRED IN A PREGNANT WOMAN, ADVISE THE PATIENT OF THE RISK OF NEONATAL OPIOID WITHDRAWAL SYNDROME AND ENSURE THAT APPROPRIATE TREATMENT WILL BE AVAILABLE.
CONCOMITANT USE OF OLICERIDINE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS, INCLUDING ALCOHOL, MAY RESULT IN PROFOUND SEDATION, RESPIRATORY DEPRESSION, COMA, AND DEATH. RESERVE CONCOMITANT PRESCRIBING FOR USE IN PATIENTS FOR WHOM ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE; LIMIT DOSAGES AND DURATIONS TO THE MINIMUM REQUIRED; AND FOLLOW PATIENTS FOR SIGNS AND SYMPTOMS OF RESPIRATORY DEPRESSION AND SEDATION.
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of oliceridine in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/21/2024
